Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease
- PMID: 20484311
- PMCID: PMC3131178
- DOI: 10.1177/1358863X10364552
Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease
Abstract
Peripheral arterial disease (PAD) is associated with major cardiovascular morbidity and mortality. Abnormalities in nitric oxide metabolism due to excess of the NO synthase inhibitor asymmetric dimethylarginine (ADMA) may be pathogenic in PAD. We explored the association between ADMA levels and markers of atherosclerosis, function, and prognosis. A total of 133 patients with symptomatic PAD were enrolled. Ankle-brachial index (ABI), walking time, vascular function measures (arterial compliance and flow-mediated vasodilatation) and plasma ADMA level were assessed for each patient at baseline. ADMA correlated inversely with ABI (r = -0.238, p = 0.003) and walking time (r = -0.255, p = 0.001), independent of other vascular risk factors. We followed up 125 (94%) of our 133 initial subjects with baseline measurements (mean 35 months). Subjects with ADMA levels in the highest quartile (> 0.84 mumol/l) showed a significantly greater occurrence of a major adverse cardiovascular event (MACE) compared to those with ADMA levels in the lower three quartiles (p = 0.001). Cox proportional-hazards regression analysis revealed that ADMA was a significant predictor of MACE, independent of other risk factors including age, sex, blood pressure, smoking history, diabetes and ABI (hazard ratio = 5.1, p < 0.001). Measures of vascular function, such as compliance, flow-mediated vasodilatation (FMVD) and blood pressure, as well as markers of PAD severity, including ABI and walking time, were not predictive. In conclusion, circulating levels of ADMA correlate independently with measures of disease severity and major adverse cardiovascular events. Agents that target this pathway may be useful for this patient population. Clinical Trial Registration - URL: http:// www.clinicaltrials.gov. Unique identifier: NCT00284076.
Figures


Similar articles
-
Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease.Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2536-40. doi: 10.1161/01.ATV.0000242801.38419.48. Epub 2006 Aug 24. Arterioscler Thromb Vasc Biol. 2006. PMID: 16931791
-
Asymmetric dimethylarginine as an independent risk marker for mortality in ambulatory patients with peripheral arterial disease.J Intern Med. 2011 Mar;269(3):349-61. doi: 10.1111/j.1365-2796.2010.02322.x. Epub 2010 Dec 22. J Intern Med. 2011. PMID: 21175900
-
Asymmetric dimethylarginine levels in Buerger's disease.Ann Vasc Surg. 2011 May;25(4):547-54. doi: 10.1016/j.avsg.2010.12.011. Epub 2011 Mar 25. Ann Vasc Surg. 2011. PMID: 21439775
-
Increased levels of symmetric dimethyl-arginine are associated with all-cause mortality in patients with symptomatic peripheral arterial disease.J Vasc Surg. 2015 May;61(5):1292-8. doi: 10.1016/j.jvs.2015.01.002. Epub 2015 Mar 13. J Vasc Surg. 2015. PMID: 25776186
-
YKL-40 levels increase with declining ankle-brachial index and are associated with long-term cardiovascular mortality in peripheral arterial disease patients.Atherosclerosis. 2018 Jul;274:152-156. doi: 10.1016/j.atherosclerosis.2018.05.006. Epub 2018 May 9. Atherosclerosis. 2018. PMID: 29783062
Cited by
-
Global trends, potential mechanisms and early detection of organ damage in SLE.Nat Rev Rheumatol. 2013 May;9(5):301-10. doi: 10.1038/nrrheum.2012.208. Epub 2012 Dec 11. Nat Rev Rheumatol. 2013. PMID: 23229448 Review.
-
Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population.PLoS One. 2015 Jun 10;10(6):e0124653. doi: 10.1371/journal.pone.0124653. eCollection 2015. PLoS One. 2015. PMID: 26061035 Free PMC article.
-
DDAH says NO to ADMA.Arterioscler Thromb Vasc Biol. 2011 Jul;31(7):1462-4. doi: 10.1161/ATVBAHA.111.228833. Arterioscler Thromb Vasc Biol. 2011. PMID: 21677286 Free PMC article. No abstract available.
-
Effects of tofacitinib therapy on arginine and methionine metabolites in association with vascular pathophysiology in rheumatoid arthritis: A metabolomic approach.Front Med (Lausanne). 2022 Nov 10;9:1011734. doi: 10.3389/fmed.2022.1011734. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36438060 Free PMC article.
-
Association of lower extremity performance with cardiovascular and all-cause mortality in patients with peripheral artery disease: a systematic review and meta-analysis.J Am Heart Assoc. 2014 Aug 13;3(4):e001105. doi: 10.1161/JAHA.114.001105. J Am Heart Assoc. 2014. PMID: 25122666 Free PMC article.
References
-
- Brevetti G, Oliva G, Silvestro A, Scopacasa F, Chiariello M. Prevalence, risk factors and cardiovascular comorbidity of symptomatic peripheral arterial disease in Italy. Atherosclerosis. 2004;175(1):131–138. - PubMed
-
- Criqui MH, Vargas V, Denenberg JO, Ho E, Allison M, Langer RD, Gamst A, Bundens WP, Fronek A. Ethnicity and peripheral arterial disease: the San Diego Population Study. Circulation. 2005;112(17):2703–2707. - PubMed
-
- Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. The New England journal of medicine. 1986;315(17):1046–1051. - PubMed
-
- Oemar BS, Tschudi MR, Godoy N, Brovkovich V, Malinski T, Luscher TF. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation. 1998;97(25):2494–2498. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical